Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cordycepin alleviates aluminium chloride-induced neurodevelopmental toxicity in zebrafish embryos by modulating inflammation and Wnt signaling.

Neurochemistry international·2026
Same author

A biomimetic strip for standardized evaluation of herbicide deposition dynamics.

Materials horizons·2026
Same author

Interacting and joint impact of oxidative balance score and insulin resistance on cardiovascular and metabolic diseases risks: a cross-sectional, population-based study.

BMC cardiovascular disorders·2026
Same author

Correction: Molecular mechanisms of α-syn abnormal phase separation in cognitive impairment induced by chronic intermittent hypoxia and the neuroprotective effects of Danshensu methyl ester.

Molecular medicine (Cambridge, Mass.)·2026
Same author

Cultivated Vegetation Shapes Diversity and Stability of Spontaneous Herbaceous Communities in Residential Green Spaces.

Ecology and evolution·2026
Same author

mTORC1-Dependent Regulation of the CCL24-CCR3 Axis Controls Granuloma Formation and Maintenance in Sarcoidosis.

Molecular and cellular biology·2026
Same journal

Prostate Cancer: Etiology, Diagnosis, and Treatment.

Serican journal of medicine·2026
Same journal

Mechanisms and Therapeutic Strategies to Overcome Enzalutamide Resistance in Advanced Prostate Cancer.

Serican journal of medicine·2026
Same journal

HOXB13-Mediated Lipid Metabolism Regulates Prostate Cancer Metastasis.

Serican journal of medicine·2026
Same journal

Acetate Metabolism in Urological Health and Disease.

Serican journal of medicine·2026
Same journal

Conditionally Reprogrammed Cells Preserve Cellular Diversity and Permit Genetic Manipulation: Implications for Cancer Heterogeneity and Tissue Regeneration.

Serican journal of medicine·2026
Same journal

Delineating the roles of HOXB13 X285K variant in prostate cancer.

Serican journal of medicine·2026
See all related articles

Related Experiment Video

Updated: Jul 1, 2026

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

PLK1: A Promising Therapeutic Target for Prostate Cancer Treatment.

Jia Peng1, Mansoureh Nouri1, Hamed Maasoumyhaghighi1

  • 1Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, Kentucky 40536, USA.

Serican Journal of Medicine
|June 30, 2026
PubMed
Summary
This summary is machine-generated.

Polo-like kinase 1 (PLK1) drives castration-resistant prostate cancer (CRPC) progression and resistance to therapies. Inhibiting PLK1, potentially with paclitaxel, offers a promising strategy to improve CRPC treatment outcomes.

Keywords:
CRPCEZH2PARPiPLK1prostate cancertreatment resistance

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Related Experiment Videos

Last Updated: Jul 1, 2026

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Prostate cancer is a leading cause of cancer mortality in men.
  • Androgen deprivation therapy (ADT) is standard for advanced prostate cancer, but resistance leads to lethal castration-resistant prostate cancer (CRPC).
  • Next-generation androgen receptor signaling inhibitors (ARSIs) are effective but face resistance challenges.

Purpose of the Study:

  • To examine the role of Polo-like kinase 1 (PLK1) in CRPC progression and treatment resistance.
  • To explore PLK1's mechanistic involvement in pathways promoting tumor growth and therapy resistance.
  • To identify potential combination therapies involving PLK1 inhibition for improved CRPC treatment.

Main Methods:

  • Review of recent studies on PLK1's function in prostate cancer.
  • Analysis of PLK1's links to oxidative stress, lipid metabolism, and androgen receptor signaling.
  • Investigation of PLK1's role in DNA repair, chromosomal stability, and resistance to targeted therapies.

Main Results:

  • PLK1 is identified as a key driver of CRPC progression and resistance to ARSIs.
  • PLK1 activation is associated with pathways promoting tumor growth and resistance.
  • PLK1 influences sensitivity to irradiation therapy and resistance to PARP inhibitors in BRCA-mutant CRPC.

Conclusions:

  • PLK1 is a critical therapeutic target in CRPC.
  • Combining PLK1 inhibition with therapies like paclitaxel may overcome resistance.
  • Targeting PLK1 offers a promising strategy to improve efficacy and outcomes in CRPC treatment.